Developer docs
API playgroundTry for free, no card

Search company profiles

FDC

Full company profile

uuid00094f6

Namestring
FDC
Legal namestring
FDC Limited
Websiteurl
fdcindia.com
Company typeenum
Public
Founded yearint
1936
Descriptiontext

FDC Limited is an Indian pharmaceutical company founded in 1936 and headquartered in Aurangabad, India, publicly traded on the Bombay Stock Exchange (ticker: FDC). The company is ranked among India's top 25 pharmaceutical companies and operates across two principal product lines: Electral, an Oral Rehydration Solution (ORS) holding over 50% market share in India's ORS segment, and Enerzal, an energy drink competing in the Rs 1,500 crore energy drinks category. FDC generates revenue primarily through the manufacture and sale of branded pharmaceutical formulations and consumer health products distributed through traditional pharmaceutical distribution networks.

The company's commercial operations are anchored by a field force of 5,000+ users deployed across 11 divisions, managing a network of more than 8 lakh doctors through the SANeForce SFA platform (in partnership since 2018). The platform provides selfie-based attendance, geo-tagging, unified doctor identification, and expense management, with vendor-side development of AI, WhatsApp, and event management modules underway. FDC's FY2026 sales reached Rs 2,170.93 crore with consolidated net profit of Rs 281.42 crore; Q4 FY2026 showed 18.89% YoY sales growth and a 167.39% YoY net profit increase, with operating margin expanding to 18.19% from 10.97%.

FDC's business model is built on branded consumer pharmaceuticals distributed through a domestic field force and traditional pharma channels, with no disclosed international footprint beyond India. The company is currently navigating two material external developments: the FSSAI's October 2025 ban on 'ORS' labelling for non-WHO-compliant beverages (which contracted the ORS market by 26% in March 2026), and an ongoing trademark infringement suit in the Delhi High Court against Johnson & Johnson/Kenvue over the eRZL electrolyte drink that allegedly infringes on FDC's Enerzal brand.

Short descriptiontext

FDC Limited is a publicly traded Indian pharmaceutical company (BSE: FDC) founded in 1936, best known for Electral, which holds over 50% of India's ORS market, and the Enerzal energy drink brand, serving consumers through a field force covering 8 lakh+ doctors across India.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
pharmaceutical manufacturing, oral rehydration solutions, prescription pharmaceuticals, consumer health products, energy drink formulations
Industry3 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAHAL
Functional Beverages (Vitamins, Probiotics, Nootropics, etc.)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Non-Alcoholic Beverages (Coffee, Tea, Soft Drinks, Water)
SECONDARYAFAFAFAJ
Medical & Clinical Nutrition Beverage Production (Oral Nutritional Supplements)
Agriculture & Food Production/Beverage Production/Functional & Nutritional Beverage Production (Energy, Sports, Fortified)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Beverage Manufacturing3121
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Beverages2080
Product category
Pharmaceutical Manufacturing
No data
Revenue model1 record
1Pharmaceutical products
TypeHardware Sales
Description

FDC Limited generates revenue through the manufacturing and sale of pharmaceutical products including oral rehydration solutions (ORS), with its Electral brand holding over 50% market share in India's ORS market, as well as other pharmaceutical formulations and consumer health products like the Enerzal energy drink.

business-standard.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Marketing or Sales, Supply Chain, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

FDC Limited manufactures and sells pharmaceutical formulations with two flagship consumer-facing brands: Electral, the market-leading oral rehydration solution (ORS) brand in India with over 50% market share, and Enerzal, a competing energy drink in the Rs 1,500 crore energy drinks segment. The company distributes these and other general pharmaceutical products via traditional pharmaceutical distribution networks and a large direct field force organized across 11 divisions that engages a network of more than 8 lakh doctors in India.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Operating profit margin improved to 18.19% from 10.97% year-over-year in Q4 FY2026
+2 more records
Product overview1 text field

FDC is one of India's top 25 pharmaceutical companies with two primary consumer-facing products: Electral (Oral Rehydration Solution) and Enerzal (energy drink). Electral dominates the ORS market with over 50% market share, while Enerzal competes in the ₹1,500 crore energy drinks segment. FDC operates across 11 divisions managing a network of more than 8 lakh doctors through field force operations.

Product and service2 records
1Electral
CategoryOral Rehydration Solutions
Description

Electral is FDC's Oral Rehydration Solution (ORS) brand and is the market leader in India's ORS segment, historically holding over 50% market share. It is used to treat dehydration and is targeted at healthcare providers and consumers via pharmaceutical distribution and the FDC field force network.

2Enerzal
CategoryConsumer Health / Energy Drinks
Description

Enerzal is FDC's energy drink brand, competing in India's Rs 1,500 crore energy drinks segment. The brand is the subject of a trademark lawsuit FDC filed in the Delhi High Court against Johnson & Johnson/Kenvue's eRZL electrolyte drink over phonetic similarity. Enerzal is targeted at consumers via pharmaceutical and retail distribution.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-01-01
Description

FDC partnered with SANeForce, a Pharma SFA software provider, for field force automation. The six-year partnership (since 2018) has deployed over 5,000 field force users across 11 divisions managing a network of over 8 lakh doctors. Features include selfie-based attendance, geo-tagging, unified doctor identification, and expense management. SANeForce is developing AI integration, WhatsApp communication, and event management modules to further enhance doctor engagement and rep efficiency.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of India's largest branded pharmaceutical manufacturers, with a comparable portfolio of formulations sold through an extensive field force into the Indian domestic market. Directly comparable as an Indian branded-pharma peer of similar scale and go-to-market model.

TypeDirect peer
Description

Fast-growing Indian branded formulations company with strong OTC and consumer health adjacencies (including OTC/electrolyte categories). Closely comparable to FDC in product mix, domestic field force intensity, and consumer-pharma crossover.

TypeDirect peer
Description

Indian branded pharmaceutical company with a similar domestic-focused formulations portfolio and strong primary-care franchise. Comparable in scale, channel mix, and therapeutic-area breadth to FDC.

4TTK Healthcare
TypeEmerging player
Description

Indian healthcare company with presence in OTC and consumer health products, including electrolyte/ORS-adjacent categories. A relevant niche competitor to FDC in the ORS/electrolyte space where Electral competes.

TypeDirect peer
Description

Major Indian pharmaceutical manufacturer with a sizable branded formulations business in India across primary and specialty care. Comparable in domestic branded-pharma orientation and field force distribution.

6Sun Pharmaceutical
TypeBroad incumbent
Description

India's largest pharmaceutical company with a broad branded and specialty portfolio. A larger, broader incumbent in the same Indian pharma space; comparable on geography and channel, but with much wider therapeutic and international reach.

TypeEmerging player
Description

Leading Indian consumer health and Ayurvedic products company that also plays in OTC health drinks and electrolytes (e.g., Glucon-D). Comparable to FDC on the consumer health/electrolyte beverage side, especially for Enerzal.

TypeBroad incumbent
Description

Large Indian pharmaceutical company with significant branded generics in India. Comparable in domestic market orientation and pharmaceutical manufacturing, though materially larger and more diversified globally.

TypeEmerging player
Description

Indian company combining pharmaceutical/OTC and consumer health products with strong domestic distribution. Comparable to FDC's consumer-pharma crossover positioning, especially in OTC and wellness adjacencies.

10Manforce/Godrej Consumer Products (consumer health arm)
TypeOthers
Description

Large Indian consumer products company with health and OTC adjacencies. Adjacent comparison for FDC's consumer-facing health brand strategy, particularly relevant to the Enerzal energy drink positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FDC

Pharmaceutical Manufacturingfdcindia.com

FDC Limited is a publicly traded Indian pharmaceutical company (BSE: FDC) founded in 1936, best known for Electral, which holds over 50% of India's ORS market, and the Enerzal energy drink brand, serving consumers through a field force covering 8 lakh+ doctors across India.

What FDC does

FDC Limited is an Indian pharmaceutical company founded in 1936 and headquartered in Aurangabad, India, publicly traded on the Bombay Stock Exchange (ticker: FDC). The company is ranked among India's top 25 pharmaceutical companies and operates across two principal product lines: Electral, an Oral Rehydration Solution (ORS) holding over 50% market share in India's ORS segment, and Enerzal, an energy drink competing in the Rs 1,500 crore energy drinks category. FDC generates revenue primarily through the manufacture and sale of branded pharmaceutical formulations and consumer health products distributed through traditional pharmaceutical distribution networks.

The company's commercial operations are anchored by a field force of 5,000+ users deployed across 11 divisions, managing a network of more than 8 lakh doctors through the SANeForce SFA platform (in partnership since 2018). The platform provides selfie-based attendance, geo-tagging, unified doctor identification, and expense management, with vendor-side development of AI, WhatsApp, and event management modules underway. FDC's FY2026 sales reached Rs 2,170.93 crore with consolidated net profit of Rs 281.42 crore; Q4 FY2026 showed 18.89% YoY sales growth and a 167.39% YoY net profit increase, with operating margin expanding to 18.19% from 10.97%.

FDC's business model is built on branded consumer pharmaceuticals distributed through a domestic field force and traditional pharma channels, with no disclosed international footprint beyond India. The company is currently navigating two material external developments: the FSSAI's October 2025 ban on 'ORS' labelling for non-WHO-compliant beverages (which contracted the ORS market by 26% in March 2026), and an ongoing trademark infringement suit in the Delhi High Court against Johnson & Johnson/Kenvue over the eRZL electrolyte drink that allegedly infringes on FDC's Enerzal brand.

FDC firmographics

Firmographics
Name
FDC
Legal name
FDC Limited
Website
https://fdcindia.com
Company type
Public
Founded year
1936
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
FDC Limited is a publicly traded Indian pharmaceutical company (BSE: FDC) founded in 1936, best known for Electral, which holds over 50% of India's ORS market, and the Enerzal energy drink brand, serving consumers through a field force covering 8 lakh+ doctors across India.
Ownership category
akta.pro rank

FDC industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Beverage Manufacturing (3121), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Beverages (2080)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAHAL
Functional Beverages (Vitamins, Probiotics, Nootropics, etc.)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Non-Alcoholic Beverages (Coffee, Tea, Soft Drinks, Water)
SECONDARYAFAFAFAJ
Medical & Clinical Nutrition Beverage Production (Oral Nutritional Supplements)
Agriculture & Food Production/Beverage Production/Functional & Nutritional Beverage Production (Energy, Sports, Fortified)

Keywords

  • Pharmaceutical manufacturing
  • Oral rehydration solutions
  • Prescription pharmaceuticals
  • Consumer health products
  • Energy drink formulations

Where FDC is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Markets served

FDC business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Marketing or Sales, Supply Chain, Technology or R&D

Revenue model

  1. Pharmaceutical products: FDC Limited generates revenue through the manufacturing and sale of pharmaceutical products including oral rehydration solutions (ORS), with its Electral brand holding over 50% market share in India's ORS market, as well as other pharmaceutical formulations and consumer health products like the Enerzal energy drink.

Distribution channels1 record

Marketing channels1 record

FDC product offering

Product offering

Core offering

FDC Limited manufactures and sells pharmaceutical formulations with two flagship consumer-facing brands: Electral, the market-leading oral rehydration solution (ORS) brand in India with over 50% market share, and Enerzal, a competing energy drink in the Rs 1,500 crore energy drinks segment. The company distributes these and other general pharmaceutical products via traditional pharmaceutical distribution networks and a large direct field force organized across 11 divisions that engages a network of more than 8 lakh doctors in India.

Product overview

FDC is one of India's top 25 pharmaceutical companies with two primary consumer-facing products: Electral (Oral Rehydration Solution) and Enerzal (energy drink). Electral dominates the ORS market with over 50% market share, while Enerzal competes in the ₹1,500 crore energy drinks segment. FDC operates across 11 divisions managing a network of more than 8 lakh doctors through field force operations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Electral Electral is FDC's Oral Rehydration Solution (ORS) brand and is the market leader in India's ORS segment, historically holding over 50% market share. It is used to treat dehydration and is targeted at healthcare providers and consumers via pharmaceutical distribution and the FDC field force network.
  • Enerzal Enerzal is FDC's energy drink brand, competing in India's Rs 1,500 crore energy drinks segment. The brand is the subject of a trademark lawsuit FDC filed in the Delhi High Court against Johnson & Johnson/Kenvue's eRZL electrolyte drink over phonetic similarity. Enerzal is targeted at consumers via pharmaceutical and retail distribution.

Quantifiable outcome

  • Operating profit margin improved to 18.19% from 10.97% year-over-year in Q4 FY2026
  • +2 more outcomes

Companies that use FDC

Customer profile

Segments1 record

Ideal customer profiles1 record

FDC technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

FDC partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SANeForcecoreTechnology or Integration · 1 January 2018FDC partnered with SANeForce, a Pharma SFA software provider, for field force automation. The six-year partnership (since 2018) has deployed over 5,000 field force users across 11 divisions managing a network of over 8 lakh doctors. Features include selfie-based attendance, geo-tagging, unified doctor identification, and expense management. SANeForce is developing AI integration, WhatsApp communication, and event management modules to further enhance doctor engagement and rep efficiency.

Scale indicators9 records

Recent moves4 records

Expansion highlights4 records

FDC competitors and assessment

Company assessment

Direct peers

  • Cipla: One of India's largest branded pharmaceutical manufacturers, with a comparable portfolio of formulations sold through an extensive field force into the Indian domestic market. Directly comparable as an Indian branded-pharma peer of similar scale and go-to-market model.
  • Mankind Pharma: Fast-growing Indian branded formulations company with strong OTC and consumer health adjacencies (including OTC/electrolyte categories). Closely comparable to FDC in product mix, domestic field force intensity, and consumer-pharma crossover.
  • Alkem Laboratories: Indian branded pharmaceutical company with a similar domestic-focused formulations portfolio and strong primary-care franchise. Comparable in scale, channel mix, and therapeutic-area breadth to FDC.
  • Lupin: Major Indian pharmaceutical manufacturer with a sizable branded formulations business in India across primary and specialty care. Comparable in domestic branded-pharma orientation and field force distribution.

Emerging players

  • TTK Healthcare: Indian healthcare company with presence in OTC and consumer health products, including electrolyte/ORS-adjacent categories. A relevant niche competitor to FDC in the ORS/electrolyte space where Electral competes.
  • Dabur India: Leading Indian consumer health and Ayurvedic products company that also plays in OTC health drinks and electrolytes (e.g., Glucon-D). Comparable to FDC on the consumer health/electrolyte beverage side, especially for Enerzal.
  • Himalaya Drug Company: Indian company combining pharmaceutical/OTC and consumer health products with strong domestic distribution. Comparable to FDC's consumer-pharma crossover positioning, especially in OTC and wellness adjacencies.

Broad incumbents

  • Sun Pharmaceutical: India's largest pharmaceutical company with a broad branded and specialty portfolio. A larger, broader incumbent in the same Indian pharma space; comparable on geography and channel, but with much wider therapeutic and international reach.
  • Dr. Reddy's Laboratories: Large Indian pharmaceutical company with significant branded generics in India. Comparable in domestic market orientation and pharmaceutical manufacturing, though materially larger and more diversified globally.

Others

  • Manforce/Godrej Consumer Products (consumer health arm): Large Indian consumer products company with health and OTC adjacencies. Adjacent comparison for FDC's consumer-facing health brand strategy, particularly relevant to the Enerzal energy drink positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

FDC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FDC leadership team

Management profile

Number of profiles

Profiles5 records

FDC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FDC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FDC

What does FDC do?

FDC Limited manufactures and sells pharmaceutical formulations with two flagship consumer-facing brands: Electral, the market-leading oral rehydration solution (ORS) brand in India with over 50% market share, and Enerzal, a competing energy drink in the Rs 1,500 crore energy drinks segment. The company distributes these and other general pharmaceutical products via traditional pharmaceutical distribution networks and a large direct field force organized across 11 divisions that engages a network of more than 8 lakh doctors in India.

Is FDC a public or private company?

FDC is a public company. It is classified as public and is currently operating.

When was FDC founded?

FDC was founded in 1936. It employs 1,001 to 5,000 people.

Where is FDC based?

FDC is headquartered in Mumbai, India, in the Asia region.

How does FDC make money?

One revenue line is on record: pharmaceutical products.

Who are FDC's main competitors?

Direct peers on record are Cipla, Mankind Pharma, Alkem Laboratories and Lupin. Emerging players are TTK Healthcare, Dabur India and Himalaya Drug Company. Broad incumbents are Sun Pharmaceutical and Dr. Reddy's Laboratories. Manforce/Godrej Consumer Products (consumer health arm) is listed as an others.

Does FDC have an API?

No public API is recorded for FDC.

What industry is FDC in?

FDC's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of CRADAHAL, Functional Beverages (Vitamins, Probiotics, Nootropics, etc.). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXStocks to Watch Today, August 28, 2026: THOMAS COOK (INDIA) LTD, Dr. Agrawals Eye Hospital, Star Cement, FDC and Great Eastern Shipping CompanyTejas Networks rallied 1.2% on a ₹1,537 crore order from TCS for BSNL 4G equipment, while Hero Motocorp increased its Ather Energy stake by ₹1,758 crore. Star Cement's Q1 profit fell 25% to ₹74 crore, and Great Eastern Shipping approved a ₹900 crore buyback. Manipal Health Enterprises posted 38% revenue growth.ScanXDelhi HC grants FDC stay on FSSAI product label noticeThe Delhi High Court granted FDC Limited an interim stay on August 26, 2026, suspending enforcement of an FSSAI notice alleging mislabeling of its products as 'electrolyte' or 'electrolyte drink'. The court allowed eight months to exhaust existing stock and update labels, with FDC saying there is no material adverse impact on its financials or operations.ScanXFDC subsidiary secures UK MHRA approval for Atropine 1.0% eye dropsFDC International Limited, a subsidiary of FDC Limited, has received marketing authorization for Atropine 1.0% eye drops from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This approval allows FDC International Limited to commercialize the ophthalmic solution in the United Kingdom, contributing to their market presence. The announcement was made on August 13, 2026.Business News TodayFDC Standalone June 2026 Net Sales at Rs 655.10 crore, up 2% Y-o-Y- Moneycontrol.comFDC reported standalone net sales of Rs 655.10 crore for June 2026, a 2% year-on-year increase from Rs 642.28 crore in June 2025. Net profit rose 8.04% to Rs 132.02 crore, while EBITDA improved 7.49% to Rs 190.18 crore during the same period. EPS increased to Rs 8.11 from Rs 7.51, and the stock closed at Rs 370.00 on August 5, 2026.Business StandardFDC consolidated net profit rises 9.17% in the June 2026 quarterFDC reported a 9.17% increase in consolidated net profit to Rs 132.49 crore for the quarter ended June 2026, compared to Rs 121.36 crore in the same quarter of the previous year. Sales grew 2.97% to Rs 667.69 crore from Rs 648.41 crore year-over-year, while operating profit margin slightly declined to 21.42% from 21.65%.ScanXFDC reports 8% profit rise to ₹1,324.9M in Q1FY26; approves green energy stakeFDC Limited reported consolidated Q1FY26 net profit of ₹1,324.9 million, an increase of 9.2% year-over-year, with revenue growing 3.0% to ₹6,676.9 million and EPS reaching ₹8.14. The Board approved an in-principle investment of up to ₹4.5 million for a 26% stake in Netra Green Energy Private Limited to enable captive solar power procurement for its Roha manufacturing unit, supporting sustainability objectives. Statutory auditors B S R & Co. LLP provided an unmodified review conclusion on the quarterly results.Business TodayFund Manager Reveals Top Portfolio Bets! Stocks Backed For Long-Term GrowthAditya Khemka, CIO at InCred Asset Management, outlined his top long-term stock convictions, naming HCG as his highest conviction pick, followed by Thyrocare and FDC. The fund manager explained that companies failing to meet structural growth expectations are removed from the portfolio, with capital reallocated to stronger opportunities. The article promotes a video discussion on how professional fund managers build conviction and identify potential wealth creators.Business TodayHealthcare sector: Bullish on HCG, Thyrocare and FDC shares, says InCred AMC CIOInCred Asset Management CIO Aditya Khemka outlined the firm's healthcare investment strategy, identifying Healthcare Global (HCG) as the top conviction pick at 15% of the PMS portfolio, followed by Thyrocare and FDC as second and third convictions respectively. The strategy favors domestic healthcare plays—hospitals, diagnostics, and branded pharma—over export-led names exposed to regulatory and tariff risks, evaluating businesses over a 12-36 month horizon rather than short-term momentum. The firm also emphasized strict risk control, citing the exit from Cngene due to structural underperformance as an example of cutting exposure when the investment thesis weakens.Business StandardFDC consolidated net profit rises 167.39% in the March 2026 quarterFDC reported a 167.39% increase in consolidated net profit to Rs 103.40 crore for the quarter ended March 2026, compared to Rs 38.67 crore in the same quarter of the previous year, with sales rising 18.89% to Rs 584.79 crore. For the full year ended March 2026, net profit grew 5.48% to Rs 281.42 crore on sales of Rs 2170.93 crore. The company's operating profit margin improved significantly in the quarter, rising to 18.19% from 10.97% year-over-year.UNI IndiaFDC Ltd Elevates Field Force Efficiency with SANeForce SFA: A 6-Year Partnership Driving Productivity Across 11 DivisionsFDC Ltd, one of India's top 25 pharmaceutical companies, has strengthened its field operations through a six-year partnership with SANeForce, a Pharma SFA software provider, with over 5,000 field forces now using the platform across 11 divisions to manage a network of more than 8 lakh doctors. The partnership, which began in 2018 after FDC tested and moved on from three different SFA vendors, has achieved zero complaints and delivered measurable efficiency through features including selfie-based attendance, geo-tagging, unified doctor identification, and expense management. SANeForce is developing AI integration, WhatsApp communication, and event management modules to further enhance doctor engagement and rep efficiency.